Gates Foundation-Backed Liquidia Plans Singapore IPO
- Company aims to seek S$300 million valuation on junior market
- Other investors include GlaxoSmithKline, NEA, Morningside
This article is for subscribers only.
Liquidia Technologies, a biotechnology firm backed by the Bill & Melinda Gates Foundation, is planning a Singapore initial public offering this year, according to people with knowledge of the matter.
The U.S. company aims to list on Singapore’s junior Catalist market at a valuation of about S$300 million ($211 million), the people said, asking not to be identified because the information is private. Liquidia is in early talks with investors including Malaysian sovereign fund Khazanah Nasional Bhd. about selling a stake before the proposed offering, according to the people.